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Abstract
Polylactic-co-glycolic acid (PLGA) based nanoparticles are biocompatible and biodegradable and
therefore have been extensively investigated as therapeutic carriers. Here, we engineered
diagnostically active PLGA nanoparticles that incorporate high payloads of nanocrystals into their
core for tunable bioimaging features. We accomplished this through esterification reactions of
PLGA to generate polymers modified with nanocrystals. The PLGA nanoparticles formed from
modified PLGA polymers that were functionalized with either gold nanocrystals or quantum dots
exhibited favorable features for computed tomography and optical imaging, respectively.
Clinical imaging modalities such as computed tomography (CT) and magnetic resonance
imaging (MRI) are routinely used for disease diagnosis and evaluation of treatment efficacy.
Molecular imaging is the specific detection of biological processes in vivo.1a It relies on
generating functionalizable probes with high payloads of contrast generating materials,
which is often accomplished using nanotechnology.1b Some of such systems were reported
previously by our group.1c–g Inorganic nanocrystals, like gold or quantum dots (QDs), are
frequently used as contrast agents for imaging in biological applications. Metallic gold
nanocrystals (AuNCs) are electron dense and exhibit a high X-ray attenuation coefficient
making them particularly suitable for CT applications.2a,b Semiconductor quantum dots
(QDs) display a broadband absorption in the UV/VIS range and a narrow emission that can
be tuned to near IR by varying the nanocrystal size and composition.2c Low photobleaching
and high fluorescence quantum yield have resulted in their widespread use in optical
imaging.2d Both, AuNCs and QDs, can be synthesized with a variety of capping ligands that
render them soluble in either organic or aqueous media2e,f and allow functionalization with
other molecules.2g,h
Polymeric nanoparticles such as poly(lactic-co-glycolic acid) (PLGA) with incorporated
drugs have high therapeutic potential.3a–c Recently, lipid-coated PLGA nanoparticles have
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been synthesized that combine liposomal characteristics of long circulation half-life and
polymeric biodegradability.3d The PLGA core is coated with soybean lecithin and further
stabilized with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy (polyethylene
glycol) 2000 (DSPE–PEG) to provide long circulation half-lives in vivo. Moreover, the
inclusion of functional PEG groups allows for attachment of targeting moieties.3d,e There is
a growing interest in ‘theranostic’ PLGA nanoparticles that, as well as therapeutics, also
contain diagnostically active materials, like inorganic nanocrystals, to enable imaging
guided therapy. Nevertheless, incorporation of controllable quantities of nanocrystals into
PLGA nanoparticles remains challenging.
In this communication we describe a novel method to add diagnostic features to lipid-coated
PLGA nanoparticles, through the integration of varying amounts of AuNCs and QDs into
the nanoparticle core, for CT and optical imaging, respectively. To that end we used an
elegant esterification reaction to conjugate AuNCs4a and CdSe core CdS–CdZnS–ZnS
multi-layer shell QDs4b to PLGA polymers in a 1 to 1 stoichiometry prior to nanoparticle
synthesis. To enhance nanocrystal payload, multiple esterifications can be performed. The
procedure is outlined in Scheme 1 (see ESI† for full details). The COOH groups of 11-
mercaptoundecanoic acid (MUA) ligands were reacted with OH groups of PLGA polymers
or OH groups of 11-mercapto-1-undecanol (MUD) ligands were reacted with COOH groups
of PLGA using dicyclohexylcarbodiimide mediated reaction with dimethyl-amino pyridine
as a nucleophilic catalyst, which results in the formation of an ester bond between the
ligands of nanocrystals and PLGA monomers. The same reaction was carried out to cross
react AuNCs at the ends of PLGA with free AuNCs to form AuNC clusters for increased
loading. PLGA polymers with chemically bound AuNCs and QDs were used to synthesize
the lipid-coated PLGA nanoparticles via a nanoprecipitation method,4c rendering a hybrid
nanoparticle that has a polyethylene glycol and soybean lecithin coating, a PLGA core, and
a high payload of nanocrystals. Upon polymer degradation in vivo, the nanocrystals can be
released, and their size range (1–10 nm) together with aqueous solubility enables their
elimination through the urinary system.4d
Fig. 1 shows negative stain TEM images of lipid-PLGA nanoparticles with encapsulated
AuNCs. Fig. 1A shows plain PLGA nanoparticles without nanocrystals incorporated. The
mean diameter of these nanoparticles was 55.7 nm with a polydispersity of 0.116 as
established by dynamic light scattering. Fig. 1B shows PLGA nanoparticles formed from
polymer–AuNCs conjugates after one round of esterification reaction (PLGA–AuNCs–×1).
The average diameter of nanoparticles was 65.5 nm with a polydispersity of 0.112. In these
formulations 8 ± 3 AuNCs per PLGA nanoparticle were included (shown by arrow). In Fig.
1C PLGA nanoparticles formed from polymers that underwent two esterification reactions
with AuNCs (PLGA–AuNCs–×2). This resulted in a dramatic increase in the number of
AuNCs to 189 ± 73 per PLGA nanoparticle and appeared uniformly distributed throughout
the nanoparticle core. The diameter of the PLGA–AuNCs–×2 increased to 98.4 nm with
0.118 polydispersity. The third repetition of the esterification reaction (PLGA–AuNCs–×3)
led to a further increase of AuNCs to 829 ± 93 per PLGA nanoparticle (Fig. 1D) and an
increased diameter of 116.6 nm with a 0.112 polydispersity. Although the size of PLGA–
AuNC nanoparticles increases as gold loading increases, the diameter of ~100 nm is still
within a favorable range for nanoparticles applied in biomedicine.5a The increase of AuNCs
loading in the nanoparticles can be observed with the naked eye as a darkening of the red/
brownish color of the nanoparticle solution (Fig. 1E). The CT contrast generated by AuNCs,
encapsulated in PLGA nanoparticles, is shown in Fig. 1F. The calculated CT attenuation of
AuNCs was 5.23 HU mM−1 and attenuation of commercially available iodine-based contrast
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agent Isovue-370 (Bracco Diagnostics Inc., NJ, USA) was found to be 4.15 HU mM−1.
Similar findings were previously reported by Kim et al.5b where gold produced higher X-ray
attenuation than an iodine contrast agent.
Fig. 2A depicts a negative stain TEM image of PLGA–QDs nanoparticles. The single
esterification reaction between MUD capped QDs and PLGA polymers resulted in several
QDs per PLGA nanoparticle. The sensitivity of optical imaging, which facilitates the
detection of low QDs payloads, as well as fluorescence quenching by QD clustering5c made
us decide not to perform multiple rounds of esterification. The absorbance and emission
spectra of PLGA–QDs nanoparticles are shown in Fig. 2B. The peak for QDs is difficult to
identify in the absorption spectrum since it shows strong scattering that increases towards
shorter wavelengths, resulting from many constituents of the nanoparticle. However the
absorption peak at 580–610 nm and the emission peak at 620 nm corresponding to QDs can
be easily identified in the excitation and emission spectra, respectively. Also, the bright
fluorescence can be observed by the naked eye using a hand held UV lamp (inset of Fig.
2B). The Cd-based QDs were used as model nanocrystals for optical applications. The low
payload of QDs limits the potential cadmium related toxicity and if needed the QDs with an
alternative and cadmium free composition can be used.
To demonstrate the capability of the nanoparticles to produce image contrast in a biological
setting, we incubated the nanoparticles with mouse macrophage cells, type J774A.1. For
PLGA–AuNCs nanoparticles cells were incubated at 0.25 mg of Au per ml of media, a
corresponding concentration of Isovue, and with media only, collected as pellets after 4
hours, and imaged on a 256-slice Brilliance iCT scanner at 140 keV. The AuNCs produced
CT contrast, detected as an increase in brightness, and cell pellets can be easily discerned, as
shown in Fig. 3A (arrow). There is no CT contrast observed in pellets from media only or
Isovue. The cell pellets with PLGA–QDs nanoparticles after 1 hour incubation were
evaluated using an IVIS fluorescence imaging system. The cell pellet with PLGA–QDs
shows strong fluorescence, while fluorescence was not detectable in cells incubated with
media (Fig. 3B). Fig. 3C shows a TEM image of cells incubated with PLGA–AuNCs, with
nanoparticles detected in the cell compartments. Fig. 3D shows a confocal image of cells
after incubation with PLGA–QDs, showing bright red fluorescence in cells.
In summary, we have demonstrated a simple method to incorporate high payloads of AuNCs
or QDs into PLGA nanoparticles through a ligand–polymer and ligand–ligand esterification
reaction, to produce diagnostically active lipid-PLGA nanoparticles. The flexibility of the
approach allows for multiple repetitions of the reaction to enhance the nanocrystal loading
inside a PLGA core. The PLGA–AuNCs showed an X-ray attenuation superior to
commercially used iodine-based contrast agents. The PLGA–QDs nanoparticles
demonstrated bright fluorescence. The in vitro experiments confirmed the suitability of
nanoparticles for biological and medical applications as image generating probes. This
method can be extended to incorporate other nanocrystals, like iron oxide, silver or silica,
into polymeric nanoparticles for imaging techniques or suitable biomedical applications.
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Fig. 1.
TEM images of lipid-PLGA nanoparticles only (A), and with AuNCs ×1 (B), AuNCs ×2
(C), and AuNCs ×3 (D); all scale bars are 50 nm. (E) Lipid-PLGA nanoparticles with
increasing amounts of AuNCs. (F) CT contrast obtained from lipid-PLGA nanoparticles
with AuNCs compared to Isovue and water at 140 kV and 250 mA (scale in Hounsfield
units).
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Fig. 2.
Lipid-PLGA nanoparticles with QDs (A) TEM image and (B) absorbance and emission
spectra; inset: lipid-PLGA nanoparticles under ambient light and UV illumination.
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Fig. 3.
Results of in vitro experiments. (A) CT image and (B) fluorescent image of cell pellets, (C)
TEM image of cells incubated with lipid-PLGA–AuNCs nanoparticles (arrows) and (D)
confocal image of cells (nuclei in blue) incubated with lipid-PLGA–QDs nanoparticles
(red).
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Scheme 1.
Procedure for chemical modification of PLGA polymers with nanocrystals.
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